Welcome to our dedicated page for SCYNEXIS SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SCYNEXIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SCYNEXIS's regulatory disclosures and financial reporting.
HANHAM ANN reported acquisition or exercise transactions in this Form 4 filing.
SCYNEXIS director Ann Hanham received new equity awards in the form of common stock and stock options. She was granted 2,875 shares of common stock at no cost and 2,875 stock options with a strike price of $3.85 per share. All 2,875 restricted stock units and all 2,875 options vest in full on the first anniversary of the grant date if she continues serving as a non-employee director. After the stock grant, she directly holds 11,577 shares of common stock.
SCYNEXIS, Inc. is registering the resale of up to 87,000,000 shares of common stock under an effective Form S-3, covering shares already held by selling stockholders and shares issuable from existing warrants.
The company also amended its certificate of incorporation to increase authorized stock from 23,750,000 to 65,000,000 shares, including an increase in authorized common stock from 18,750,000 to 60,000,000 shares. Stockholders approved this change at the June 25, 2026 annual meeting, held before a 1-for-8 reverse stock split that took effect on May 29, 2026. Certain warrants become exercisable following the authorized share increase, with pre-funded warrants priced at $0.0001 per share and common warrants at $1.20 per share, all on a pre-split basis.
SCYNEXIS, Inc. has approved and implemented a one-for-eight reverse stock split of its common stock, together with a reduction in authorized shares. Effective May 29, 2026, every eight issued and outstanding shares were combined into one share, and authorized common shares were reduced from 150,000,000 to 18,750,000 with no change in par value.
The reverse split applies proportionately to all stockholders and adjusts the share counts and, where applicable, exercise prices of stock options, restricted stock units and warrants. No fractional shares will be issued; holders entitled to fractions will receive cash instead. SCYNEXIS common stock is scheduled to begin trading on Nasdaq on a split-adjusted basis on June 1, 2026 under the symbol SCYX with a new CUSIP of 811292 309.
SCYNEXIS, Inc. held a special stockholder meeting where investors approved an amendment to its certificate of incorporation to implement a reverse stock split and decrease authorized shares. Stockholders cast 44,826,378 votes for the proposal, 6,708,960 against, and 102,965 abstaining, out of 79,442,633 shares entitled to vote.
Following this approval, the Board chose a one-for-eight reverse stock split ratio, effective May 29, 2026. Every 8 issued and outstanding shares of common stock will convert into 1 share, and authorized common shares will be reduced from 150,000,000 to 18,750,000 without changing par value.
The reverse split will proportionately affect all existing shares, as well as the share counts under equity compensation plans, options, RSUs, and warrants, with corresponding increases in option and warrant exercise prices. No fractional shares will be issued; holders entitled to fractions will receive cash instead. SCYNEXIS common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on June 1, 2026 under the existing ticker SCYX, with a new CUSIP number 811292 309.
SCYNEXIS, Inc. ownership disclosure: CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 3,956,319 shares, representing 6.2% of the common stock. The reported holdings consist of 2,086,960 Shares plus Shares issuable upon exercise of warrants; certain Warrants are exercisable only to the extent they do not cause holdings to exceed 4.99% or 9.99%. Shares outstanding were 62,051,330 as of March 31, 2026. Heights Capital serves as investment manager to CVI and may exercise voting and dispositive power over the reported Shares.
SCYNEXIS, Inc. reported a Q1 2026 net loss of $21.3 million, widening from $5.4 million a year earlier, mainly due to an $8.0 million in-process R&D charge for acquiring SCY-770 and higher operating costs. Research and development expense rose to $12.4 million, while selling, general and administrative expense increased to $4.6 million, including $0.8 million of financing-related costs. A warrant fair value loss of $5.2 million also weighed on results. Cash, cash equivalents and investments were $72.4 million as of March 31, 2026, supported by a March 2026 private placement with gross proceeds of $40.0 million. The company believes these resources fund operations for at least 12 months and is advancing SCY‑770 for autosomal dominant polycystic kidney disease and SCY‑247 for invasive fungal infections.
SCYNEXIS, Inc. filed a prospectus for the resale of up to 87,000,000 shares of Common Stock by the selling stockholders. The 87,000,000 shares comprise 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares.
The company will not receive proceeds from these resales, except for cash exercises of the Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. The shares were issued in a March 30, 2026 private placement at purchase prices of $0.92 per share with accompanying warrants and $0.9199 per Pre-Funded Warrant with accompanying warrants. The registration was filed to satisfy registration rights in the Purchase Agreement and related Registration Rights Agreement.
SCYNEXIS, Inc. registered up to 87,000,000 shares of Common Stock for resale by the purchasers in its March-April 2026 private placement (the "Selling Stockholders"). The registration covers 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares issuable upon exercise.
The company will not receive proceeds from resales, except for any cash exercises of Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. Shares outstanding were 79,442,633 as of April 1, 2026. The Common Stock last traded at $0.93 on April 30, 2026.
SCYNEXIS, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Proposals include electing six directors, ratifying Deloitte & Touche LLP, an advisory say-on-pay vote and say-on-pay frequency, and governance items.
The company seeks approval to amend its 2024 Equity Incentive Plan to increase the share reserve by 9,600,000 shares and to amend its certificate of incorporation to raise authorized common stock to either 60,000,000 or 300,000,000 shares, depending on a separate reverse stock split outcome. SCYNEXIS had 79,442,633 shares of common stock outstanding and entitled to vote as of April 27, 2026.